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Background: Vitamin D (25-hydroxyvitamin D; 25[OH]D) deficiency (VDD) is highly prevalent in chronic kidney
disease. The aim of this study was to evaluate the effect of oral ergocalciferol supplementation on requirement of
erythropoietin (EPO) and active vitamin D analogues, and hospitalization rate in maintenance hemodialysis (HD)
patients.
Methods: This retrospective cohort study included 186 patients who were on HD for 3 months and had 25(OH)D
levels < 30 ng/ml. Over 1-year period, 107 patients were supplemented with protocol-based ergocalciferol (D2
group) and 79 were not (control). Parameters of erythropoiesis and bone-mineral metabolism, and monthly doses
of EPO and paricalcitol were assessed at 6- and 12- months of ergocalciferol supplementation. Total hospitalizations
were recorded for the same year.
Results: Baseline characteristics were similar across two arms except higher serum ferritin, transferrin saturation and
prevalence of stroke in D2 and higher coronary artery disease in control group with overall mean ± SD 25(OH)D
level of 16.8 ± 7 ng/ml. At 12 months, 25(OH)D levels increased significantly in D2 group compared to control
(30.5 ± 11.7 vs. 14.2 ± 9.3 ng/ml; p < 0.001). The EPO dose remained same with no difference in hemoglobin
values between the two groups during the intervention period. On multivariate regression which included
above variables there was no effect of ergocalciferol treatment on EPO dose (p = ns). Hospitalization rate was
similar in two arms; however, ergocalciferol treatment inversely associated with paricalcitol dose (β ± SE = −10.
4 ± 2.8; p < 0.001).
Conclusions: One-year of ergocalciferol supplementation was not associated with reduction in EPO
requirement or hospitalization rate in HD patients with VDD. Further studies are warranted to determine
definitive role of nutritional vitamin D in these patients.
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Vitamin D deficiency (VDD) has prevalence as high as
92 % in patients with chronic kidney disease (CKD) and
end-stage renal disease (ESRD) and it has been associ-
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The Kidney Disease Improving Global Outcome
(KDIGO) initiative recommends that nutritional vitamin
D is used to correct VDD in addition to active forms of
vitamin D in ESRD patients [7]. Active vitamin D, either
as the native hormone 1,25-dihydroxy vitamin D
(1,25(OH)2D) or as one of its synthetic analogs (paricalci-
tol, doxercalciferol, etc.), is conventionally used to correct
low levels of 1,25(OH)2D that are caused by loss of renal
1-α-hydroxylase enzyme function. The KDIGO rationale
for recommending nutritional vitamin D supplementation
is based on the emerging notions that the 1-α-hydroxylasele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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patients and that even low amounts of extra-renally
produced 1,25(OH)2D may be important for local tissue
function [8]. Basic research has shown that by binding
to ubiquitous vitamin D receptor, locally produced
1,25(OH)2D exerts autocrine and paracrine effects includ-
ing regulation of cellular proliferation and differentiation,
modulation of immune system function, inhibition of
renin synthesis and insulin production, etc.[9].
Anemia is a common complication of ESRD, primarily
the consequence of reduced EPO production and of
uremia- and resultant hyperparathoyroidism-related
resistance to this hormone. It has been suggested that
nutritional vitamin D may be effective in reversing
EPO resistance via effects of extra-renally produced
1,25(OH)2D on inflammation and insulin resistance.
Recent clinical studies have suggested that use of nu-
tritional vitamin D may lower the dose requirement
of EPO simulating agents (ESA) in ESRD patients on
maintenance hemodialysis (HD) [2, 10–12]; none of
these studies, however, had a control arm. We present
here a one-year clinical study with primary aim to
examine the effect of ergocalciferol supplementation
on EPO dose requirements in maintenance HD pa-
tients with VDD. Secondary objectives were to moni-
tor the effect of ergocalciferol supplementation on
parameters of mineral metabolism and on the rate of
hospitalization.Methods
Study design
The study had a retrospective cohort design with 1-year
follow-up in prevalent HD patients from three free-
standing dialysis clinics that are located in the same
urban area, managed by same administration and staffed
by nephrologists of the University of Texas Health Sci-
ences Center at San Antonio who follow the same pol-
icies and practices. The study protocol was approved by
the local institutional review board and is in accordance
with the ethical standards of the Declaration of Helsinki.Study population
Medical records of all 239 ESRD patients receiving HD
at the three clinics between January 2011 and January
2012 were reviewed. Patients were included in the study
if they were 18 years of age or older, initiated dialysis at
least three months prior to January 2011, received HD
treatment thrice weekly, had the serum 25-hydroxy vita-
min D [25(OH)D] level checked with VDD, i.e.,
25(OH)D level < 30 ng/ml. After exclusion of 40 subjects
for < 3 months enrollment in the HD program and 13
subjects for 25(OH)D levels ≥ 30 ng/ml, the study popu-
lation included a total of 186 patients.Ergocalciferol (D2) vs control group
Following the KDIGO-2009 guidelines which suggest
that in CKD 3-5D, 25(OH)D levels might be measured
and VDD and insufficiency be corrected using treatment
strategies recommended for the general population (2C
level) [7], University nephrology practice started measur-
ing the 25(OH)D levels in 2010 and ergocalciferol cap-
sules were purchased in the bulk to be administered by
the nursing staff to the patients with VDD during HD
treatment to avoid the need for filling the prescription.
Due to some administrative and technical difficulties,
only one of the three dialysis clinics could start ergocal-
ciferol administration in January 2011, and the other two
units started in 2012. One-hundred-seven VDD patients
from the first dialysis clinic received oral ergocalciferol
with dosing and schedule as recommended by KDIGO
(Table 1; D2 group); whereas, 79 VDD patients from the
other two dialysis units served as control group, i.e., they
were subjected to the same monitoring as the D2 group
but without ergocalciferol treatment.Measurement of demographic, biochemical and clinical
data
Information collected at the beginning of the study in-
cluded demographics, history of diabetes, hypertension,
cardiovascular disease, stroke, cancer and dialysis vin-
tage. Laboratory data were collected at baseline, 6 and
12 months, and included hemoglobin, serum iron, total
iron binding capacity, ferritin, calcium, phosphorus, al-
bumin, and intact parathyroid hormone (iPTH). Infor-
mation was collected regarding monthly administered
dose of EPO (IU/month), active vitamin D analog pari-
calcitol (μg/month) and iron sucrose (mg/month) for the
same three time periods. Adjustments of EPO and iron
dose were performed by staff nephrologists with target
hemoglobin 10–12 g/dL during early period of the study.
However, target hemoglobin was changed to 10–11 g/dL
during the middle of the study in accordance with
centers of Medicare and Medicaid services (CMS)
guidelines. Adjustments of paricalcitol dose were made to
keep iPTH between 150 and 400 ng/ml. Serum 25(OH)D
levels were analyzed with a chemiluminescence assay
(Arup, Salt Lake City, Utah) which measures the combin-
ation of 25(OH)D2 and 25(OH)D3 levels. Other lab pa-
rameters were measured using standard techniques at the
University Hospital Centralized Clinical Laboratory.Follow-up cohort
In 2012, the other two units also started ergocalciferol
supplementation following the same protocol. We col-
lected same information including loboratory data,
monthly administered EPO, paricalcitol and venofer
doses in the whole study population for the next 2 years.
Table 1 Ergocalciferol Supplementation Protocol
25(OH)D Ergocalciferol dose Duration (months) Comment
<5 ng/ml 50,000 IU PO/Week
x 12 weeks, then monthly
6 Measure 25-OH D after 6 month and repeat course based on level
5–15 ng/ml 50,000 IU PO/Week
x 4 weeks, then monthly
6 Same as above
16–30 ng/ml 50,000 IU PO/Month orally 6 Same as above
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Summary statistics for demographic, dosing, and labora-
tory variables were computed as follows: continuous var-
iables were described using mean ± standard deviation
(SD) or median with interquartile ranges (IQR) as appro-
priate, while categorical variables were described with
percentages. Continuous variable were accessed using
Mann Whitney U Test. The categorical variables were
compared using Chi-square test. For continuous labora-
tory measures, we fit a linear mixed-effect model with
time and treatment effects in order to identify time
trends within the follow-up period and associations with
treatment.
We examined the effects of multiple variables on EPO
and paricalcitol doses simultaneously using multiple re-
gression within a linear mixed-effect model. We consid-
ered demographics, comorbidities, and laboratory values
as predictors alongside ergocalciferol treatment. Because
the number of predictor variables was large, we included
variables in the mixed-effect regression if these had uni-
variate associations with the outcome (p < 0.1). To iden-
tify temporal associations with treatment, we tested the
Time x Treatment interaction. This interaction assesses
the effect of ergocalciferol supplementation on the
monthly EPO or paricalcitol dose depending on time/
duration of follow-up, i.e., at month 6 and 12. We per-
formed logistic regression to determine effect of ergocal-
ciferol treatment on the probability of hospitalization
(hospitalization or not). We considered the demograph-
ics, baseline comorbidities and laboratory measures as
potential predictors of hospitalizations, and included
these in the logistic regression if there was evidence of a
univariate association (p < 0.1) with the outcome. All
calculations were done using R software (Version 3+,
Vienna, Austria).
Outcomes
The primary outcome was the monthly dose of EPO and
secondary outcome included dose of paricalcitol by the
end of the study period and number of hospitalization.
Records of the monthly quality assurance and perform-
ance improvement meetings were reviewed to accurately
capture all hospitalizations. A visit to emergency room
was not considered a hospitalization. Since the strongest
association between 25(OH)D levels and outcomes
has been seen in patients with severe VDD[8, 13], weperformed a subgroup analysis in patients with
25(OH) D level <15 ng/ml. Based on the fact that
vitamin D supplementation might improve erythropoi-
esis through better regulation of bone turnover with
control of secondary hyperparathyroidism, a subgroup
analysis was performed in patients in the D2 group
who had the largest drop in PTH levels.
Results
Table 2 shows the baseline characters of the study popu-
lation including demographic, clinical history, laboratory
parameters and monthly administered doses of iron su-
crose, EPO, and paricalcitol. The patients in the control
group were younger, had more coronary artery disease
(CAD) and less cerebrovascular disease (CVD). The pa-
tients in the D2 group had higher 25(OH)D level, serum
iron saturation (TSAT) and ferritin compared to the
controls at baseline. Eighty-five percent of the study
population consists of Hispanic race. As shown in
Table 3, the D2 group experienced a significant increase
in 25(OH)D levels from 16.2 ± 7.5 ng/ml at baseline to
30.6 ± 11.7 ng/ml at end of study, while levels remained
low in the control group. Vitamin D sufficiency
(25[OH]D > 30 ng/ml) was achieved in 45 % of the D2
group at 6 months and in 50 % at 12 months, while only
2.5 % of the control group was vitamin D sufficient at
12 months.
Erythropoietin dose requirement: primary outcome
As shown in Table 3, there was no difference in adminis-
tered EPO dose between the two groups at different time
points (Fig. 1, univariate analysis). During the study,
hemoglobin concentration decreased in both the groups
without significant between-group difference; this drop
in hemoglobin was driven by interim change of the CMS
recommendations for hemoglobin target goal. Ferritin
and TSAT increased in the controls and decreased in
the D2 group over 12 months, and they tended to
equalize between groups by study end, although in
group comparisons both parameters remained signifi-
cantly higher in the D2 group. Albumin levels increased
in the intervention group over 1 year and despite start-
ing from numerically lower baseline levels, they were
higher than control at the end of the study. In univariate
analysis, EPO dose correlated inversely with hemoglobin,
ferritin and TSAT (all p < 0.001) and positively with iron
Table 2 Baseline Characteristics of The Study Population
Total Control Ergocalciferol p value
(n = 186) (n = 79) (n = 107)
Demographics (mean ± SD)
Age, y 57.6 ± 13 55.2 ± 11.9 59.4 ± 13.2 0.01
Male, no. (%) 92 (49.5) 40 (50.6) 52 (48.6) ns
Vintage, y 5.9 ± 4 6.3 ± 4.1 5.6 ± 3.2 ns
Co-Morbidities, number (%)
Diabetes 128 (68.8) 51 (64.6) 77 (72) ns
CAD 90 (48.4) 52 (65.8) 38 (35.3) <0.001
Hypertension 172 (92.5) 72 (91.1) 100 (93.5) ns
CVA 23 (12.4) 3 (3.8) 20 (18.7) 0.003
Cancer 7 (3.8) 1 (1.3) 6 (5.6) ns
Laboratory Parameters (mean ± SD)
Vitamin D level, ng/ml 16.8 ± 7 19.2 ± 6.8 16.2 ± 7.5 0.03
Hemoglobin, g/dl 11.1 ± 1 11.2 ± 1.1 11 ± 1.4 ns
TSAT, % 31.6 ± 16 27.5 ± 10 34.7 ± 18 <0.001
Ferritin, mg/dl 665 ± 383 538 ± 269 759 ± 425 <0.001
Calcium, mg/dl 9.1 ± 1 9.2 ± 0.7 9.1 ± 0.7 ns
Phosphorus, mg/dl 5.2 ± 2 5.1 ± 1.4 5.3 ± 1.7 ns
PTH, pg/ml median [IQR] 294 [178, 428] 283 [162, 408] 308 [184, 490] ns
Albumin, mg/dl 4.1 ± 0.01 4.2 ± 0.4 4 ± 0.3 ns
Medications (median [IQR])
Iron sucrose, mg/month 200 [0,287] 200 [25,400] 150 [0,250] ns
EPO, IU/Month 26000 [12175, 48000] 26000 [12350, 49450] 27500 [13200, 48000] ns
Paricalcitol, μg/month 26 [12, 39] 26 [10.5, 42] 25 [12.5, 39] ns
Table 3 Primary and Secondary Outcomes and Related Variables at Different Time Points in 2 Groups
Control Group Ergocalciferol Group p value
Control
vs ergo
Variable Baseline 6 months 12 months p for
trend
Baseline 6 months 12 months p for
trend
Vitamin D level, ng/ml 19.2 ± 6.8 19.7 ± 8.3 14.2 ± 9.3 0.002 16.2 ± 7.5 29.5 ± 9.9 30.6 ± 11.7 <0.001 <0.001




13[6.5,27] 0.01 27.5[13.2, 48] 26[16.4, 45.5] 23.4[9.5, 39] 0.02 ns
Hemoglobin, g/dl 11.2 ± 1.1 11.4 ± 1 10.7 ± 1.3 <0.001 11 ± 1.4 11.4 ± 1.5 10.9 ± 1.4 0.02 ns
TSAT, % 27.5 ± 10.1 31.6 ± 12.6 29.9 ± 10.9 0.03 34.7 ± 18 32.5 ± 12.2 31.7 ± 13.9 ns 0.02
Ferritin, mg/dl 538 ± 269 556 ± 260 614 ± 244 0.04 759 ± 425 691 ± 376 691 ± 370 ns 0.01
Albumin, mg/dl 4.2 ± 0.4 4.2 ± 0.2 4.2 ± 0.3 ns 4 ± 0.3 4.1 ± 0.3 4.3 ± 0.6 <0.001 <0.001
Iron sucrose, mg/month 260 ± 272 164 ± 151 199 ± 274 0.03 194 ± 231 180 ± 173 143 ± 162 ns ns
Paricalcitol dose μg/
month
26 [10.5, 42] 26[13, 51.5] 39[23.5, 52] 0.002 2512.5, 39] 24[12, 39] 20[9, 39] ns <0.001
Calcium, mg/dl 9.2 ± 0.7 9.2 ± 0.7 9.3 ± 0.8 ns 9.1 ± 0.7 9.4 ± 0.7 9.1 ± 0.8 <0.001 <0.001














Hospitalization n/year (%) 28 (35) 37 (35) ns
Data is presented either as mean ± SD or median [IQR] depending on the distribution
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Fig. 1 The monthly requirement of Erythropoietin dose (median [IQR]) over 1 year period in hemodialysis patients receiving ergocalciferol (n = 107,
blue) or control (n = 79, red), p = ns
Table 4 Multiple regression analysis within a linear mixed-effect
model with EPO dose as dependent variable and other laboratory
and clinical data entered
Variable Estimate ± SE p value
(Intercept) 110.2 ± 19.5 <0.001
Hemoglobin −3.3 ± 0.9 <0.001
TSAT −0.3 ± 0.1 0.004
Ferritin −0.01 ± 0.0 0.01
Venofer treatment 0.01 ± 0.01 ns
Calcium −2.7 ± 1.8 ns
Phosphorus −0.7 ± 0.8 ns
CVA −3.7 ± 6.6 ns
Effect of time at 6 months 0.13 ± 3.31 ns
Effect of time at 12 months −7.50 ± 3.31 0.02
Effect of ergocalciferol at 6 months 0.96 ± 4.36 ns
Effect of ergocalciferol at 12 months −0.84 ± 4.35 ns
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ation with ergocalciferol treatment or 25(OH)D levels,
or other demographic and clinical variables. In multiple
regression including all the above variables (with p < 0.1),
the variation in EPO dose was explained by the levels of
hemoglobin (p ≤ 0.001), ferritin (p = 0.004) and iron satur-
ation (p = 0.01) but, notably, not by ergocalciferol treat-
ment (Table 4).
Paricalcitol dose requirement and hospitalization:
secondary outcomes
The paricalcitol dose requirement increased substantially
by the end of the study in the control group but
remained stable in the D2 group (Fig. 2). The PTH levels
were not different between groups even though overtime
they decreased mildly but significantly in the D2 group
(Table 3). By the end of the study, the D2 group had sig-
nificantly higher serum phosphorus compared to control
group. In univariate analysis, paricalcitol dose correlated
directly with presence of diabetes (p = 0.02), CAD (p <
0.001) and with calcium levels (p = 0.02), but not with
demographic variables, serum phosphorus, iPTH and
25(OH)D levels. In multiple regression that included all
the above variables (with p < 0.1), the reduction inparicalcitol dose correlated with ergocalciferol treatment
(p < 0.001; Table 5).
Approximately one third of all participants were hospi-
talized during the study period. The number of
hospitalization correlated positively with the presence of
Fig. 2 The monthly requirement of paricalcitol dose (median [IQR]) over 1 year period in hemodialysis patients receiving ergocalciferol (n = 107,
blue) or control (n = 79, red), p < 0.001
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there was no difference in hospitalization rate in the
ergocalciferol and control groups (Table 6).
Follow-up cohort
On univariate analysis, no relationship was found
between the serum 25(OH)D levels and monthly EPO
dose (Fig. 3).Table 5 Multiple regression analysis within a linear mixed-effect
model with paricalcitol dose as dependent variable and other
laboratory and clinical data entered
Variable Estimate ± SE p value
(Intercept) 0.5 ± 11.3 ns
Diabetes 6.6 ± 3.3 0.04
Cancer 14.3 ± 8.1 ns
CAD 10.1 ± 3.2 0.002
Calcium 2.2 ± 1.2 0.06
PTH 0.0 ± 0.0 ns
Effect of time at 6 months 2.8 ± 2 ns
Effect of time at 12 months 8 ± 2 <0.001
Effect of ergocalciferol at 6 months −3.8 ± 2.8 ns
Effect of ergocalciferol at 12 months −10.4 ± 2.8 <0.001Subgroup analysis
25(OH)D <15 ng/ml
Fifty patients in the D2 group and 40 in the control
group started the study with 25(OH)D <15 ng/ml. Simi-
lar to the primary analysis, subanalysis of these subjects
with severe VDD, showed no effect of ergocalciferol
treatment on EPO requirements, but it associated with
lower administration of paricalcitol during the period of
observation. The hospitalization rate was the same be-
tween the subgroups.
D2 group with largest decrease in PTH levels
Twenty-seven of 107 patients in the D2 group had me-
dian drop of PTH (−221 pg/ml [IQR, −445, −120]), as
compared to rest of the 80 patients (78 pg/ml [IQR, −14,
196]. The monthly EPO dose in these 27 patients did
not change over 12 months of ergocalciferol supplemen-
tation (ΔEPO 230 IU/Month [IQR, −15500, 9200]), des-
pite the fact that overall EPO requirement decreased in
the study population due to CMS guideline changes.
Discussion
In this study, administration of nutritional vitamin D2
did not result in reduction of EPO requirement in
patients undergoing maintenance hemodialysis despite
Table 6 Multiple regression analysis within a linear mixed-effect
model with hospitalization rate as dependent variable and other
laboratory and clinical data entered
Variable Log Odds ± SE OR [CI95] p value
Diabetes 1.2 ± 0.4 3.4 [1.5, 7.5] 0.003
Hypertension 1.0 ± 0.8 2.9 [0.6, 14.4] ns
Hemoglobin −0.4 ± 0.1 0.7 [0.5, 0.9] 0.009
25(OH)D level 0.006 ± 0.02 1.01 [0.9, 1.05] ns
Ergocalciferol −0.2 ± 0.3 0.8 [0.4, 1.5] ns
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was no reduction in the hospitalization rate; however,
we observed a significant reduction in requirement of
active vitamin D analogue dosage. In additional analyses,
similar results were found in dialysis patients with severe
VDD.
Our study is consistent with a recent randomized con-
trolled trial of 6-month duration which showed no effect
of nutritional vitamin D supplementation on EPO re-
quirement [14]. We complement this information with
an extended follow-up of 12 months in a study popula-
tion consisting of 85 % Hispanics and 70 % diabetics.
These results are of importance since VDD has been as-
sociated with many complications related to diabetesFig. 3 The univariate association of 25(OH)D levels (mean ± SD) with mont
36 months of observation, p = nsand there is lack of information on VDD in Hispanics
[15, 16]. Our data, however, is at odds with previous in-
vestigations: Matias et al. reported 25 % reduction in use
of darbepoetin after 6 months of cholecalciferol supple-
mentation in 158 hemodialysis patients [2]; Rianthavorn
et al. demonstrated reduction in ESA dose after 12 weeks
of ergocalciferol administration in 10 CKD stage V pa-
tients aged <18 years [10]; in two other studies, 4–6
months of ergocalciferol administration reduced the
dose of ESA in approximately 60 % of patients [11, 12].
Of note, all these studies had shorter duration, smaller
sample size and lacked control group. We followed
KDOQI guidelines to correct VDD in our dialysis popu-
lation, where an oral weekly dose of 50,000 IU D2/D3
for 4–12 weeks is recommended for mild to severe vita-
min D deficiency (Table 1). In our study, the recom-
mended supplementation dose was sufficient to correct
hypovitaminosis D in half of the patients on mainten-
ance HD; however, the study leaves it unanswered
whether higher dose or frequency of vitamin D may have
resulted in higher rate of vitamin D sufficiency and de-
crease in EPO utilization in our patients. Nonetheless,
we observed that the patients who achieved clearly high
25(OH)D levels also did not have lower EPO require-
ments (results not shown). Moreover, in a recentlyhly EPO dose (median [IQR]) in the entire study population over
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achieved vitamin D sufficiency with 12 weeks of weekly
50,000 U of ergocalciferol treatment. Despite this rate of
sufficiency, the authors did not report any difference in
hemoglobin values or use of EPO in treatment and pla-
cebo arm over 12 weeks of treatment period [17].
Furthermore, consistent with the shorter duration
DIVINE study [17], we did not find beneficial effects of
vitamin D supplementation on the hospitalization rate in
our patients. The effect of Vitamin D has not been pre-
viously reported on hospitalization in the chronic dialy-
sis population in a longer study like ours [17], but the
results of the present study are consistent with one con-
ducted in critically ill non-ESRD patients, in whom ad-
ministration of vitamin D did not reduce the lengths of
ICU or hospital stay, the hospital mortality or the 6-
month mortality [13]. Similar to previous studies [2, 18],
we found that ergocalciferol administration reduced the
need for active vitamin D analogues while the effects on
serum calcium and phosphorus were negligible. We ob-
served a significant decrease in iPTH in the treatment
arm, but levels were not different compared to the con-
trol arm. These findings, however, remain difficult to be
interpreted because we did not collect information about
the use of phosphate binders and serum 1,25(OH)2D
levels.
In many studies, the association between serum
25(OH)D levels and clinical outcomes was the strongest
when the VDD was most severe. Based on this, we con-
ducted additional analyses in the subgroup of patients
with 25(OH)D level < 15 ng/ml, but found the same re-
sults as in the main study. Furthermore, over 2 years of
additional observation, we did not find any relationship
between vitamin D level and ESA dose, nor the duration
of ergocalciferol treatment had any effect on ESA
dosing.
Numerous mechanisms have been proposed to explain
the potential benefit of vitamin D on erythropoiesis: a
direct effect on erythroid precursor proliferation and/or
an indirect one via reduction of inflammation and sec-
ondary hyperparathyroidism [19, 20]. In our study, we
observed a significant increase in albumin in the treat-
ment arm suggestive of reduction in inflammation; how-
ever, this did not associate with a decrease in ESA
requirement. At our center, we prefer to reduce the dose
of active vitamin D analogues rather than drastic decrease
in iPTH levels to avoid vitamin D analogues associated
complication such as hypercalcemia, hyperphosphatemia
and adynamic bone disease while still maintaining iPTH
levels within recommended range by KDIGO. This ap-
proach could have negated the beneficial effect of reduced
iPTH level on ESA resistance. Although in a subanalysis
of patients with the largest drop in iPTH level, we did not
observe any reduction in ESA requirement. Nevertheless,our results are in alignment with recently published
studies demonstrating no pleiotropic effects of nutritional
D supplementation on the 24-h BP, arterial stiffness and
cardiac function [21], or markers of cardiovascular risk,
inflammation, muscle function or subjective health pa-
rameters in dialysis patients [22]; or chronic obstructive
pulmonary disease (COPD) exacerbation and physical
performance in COPD patients [23, 24], or asthma exacer-
bation [25].
Strengths of our study include the direct administra-
tion of intervention by the clinic staff ensuring 100 %
adherence, presence of a control arm, long duration of
follow-up, relatively large sample size and the very con-
spicuous differences in 25(OH)D status between groups.
The major flaw of the study was the change in the target
hemoglobin recommended by CMS in the middle of the
study, even though the rate of drop in the hemoglobin
was not different in the two groups. Due to retrospective
nature of the study there were many significant con-
founding factors. The multivariable analysis could ameli-
orate these factors to some extent; however, is not
infallible. Additionally, we could not account for residual
confounding. Lastly, the majority of patients were
Hispanic; therefore, our study population was not ne-
cessarily representative of the general North-American
HD population. Nevertheless, our study adds invalu-
able information to the emerging literature failing to
demonstrate the beneficial effect of vitamin D supple-
mentation in different populations.
Conclusion
The supplementation of vitamin D deficiency with ergo-
calciferol is a simple and cost effective measure but we
were unable to demonstrate its benefit on EPO require-
ment and hospitalization rate in hemodialysis patients.
There is a need for large prospective trials to support
the KDIGO guidelines to routinely supplement this
population with nutritional vitamin D.
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